Suppr超能文献

基于分子对接的单核细胞增生李斯特菌中抑制分选酶A的化合物虚拟筛选

Molecular docking based virtual screening of compounds for inhibiting sortase A in L.monocytogenes.

作者信息

Rashidieh Behnam, Madani Zohreh, Azam Mahtab Khoshnejad, Maklavani Saeedeh Khalesi, Akbari Newsha Ramezani, Tavakoli Shaghayegh, Rigi Garshasb

机构信息

Vira Vigene research institute, Tehran, Iran.

Department of Biology, Faculty of Science, Behbahan Khatam Alanbia University of Technology, Behbahan, Iran.

出版信息

Bioinformation. 2015 Nov 30;11(11):501-5. doi: 10.6026/97320630011501. eCollection 2015.

Abstract

Listeriosis is considered as an important public health issue. Sortase A (srtA) is an enzyme with catalytic role in L. monocytogenes that breaks the junction between threonine and glycine in the LPXTG motif (a key motif in internalin A (InlA) that plays an important role in listeriosis). Inactivation of srtA was shown to inhibit anchoring of the invasion protein InIA. This is in addition to inhibiting peptidoglycan-associated LPXTG proteins. Therefore, it is of interest to inhibit strA using potential molecules. Here, we describe the design of an inhibitor with high binding affinity to srtA with the ability to prevent the attachment of srtA to the LPXTG proteins such as InIJ. A homology model of Listeria monocytogenes Sortase A was developed using MODELLER (version 9.12). We screened StrA to 100,000 drug-like ligands from the Zinc database using Molecular docking and virtual screening tool PyRX). Pharmacokinetic analysis using the FAFDrugs(3) web server along with ADME and toxicity analysis based on Lipinski rule of five were adopted for the screening exercise followed by oral toxicity check using PROTOX (a server) for every 10 successive hits. The results from PROTOX server indicated that Lig #1 (with LD50 of 2000mg/kg) and Lig #7 (with LD50 of 2000mg/kg) have toxicity class 4 and Lig #3 (with LD50 of 14430mg/kg) has toxicity class 6. Subsequent modifications of these structures followed by FAFDrugs(3) analysis for high bioavailability value selected Lig #7 according to Lipinski rules of five. Thus, Lig #7 with IUPAC name ((R)-4-{(S)-1-[(S)-2-Amino-4-methylvaleryl]-2-pyrrolidinyl}-1-[(S)-1-(ethylamino) carbonyl-propylamino] -2-propyl-1, 4- butanedione) is suggested as a potential candidate for srtA inhibition for further consideration.

摘要

李斯特菌病被视为一个重要的公共卫生问题。分选酶A(srtA)是一种在单核细胞增生李斯特菌中具有催化作用的酶,它能破坏LPXTG基序(内化素A(InlA)中的一个关键基序,在李斯特菌病中起重要作用)中苏氨酸和甘氨酸之间的连接。已表明srtA的失活会抑制入侵蛋白InIA的锚定。这除了抑制与肽聚糖相关的LPXTG蛋白外。因此,利用潜在分子抑制srtA是很有意义的。在此,我们描述了一种对srtA具有高结合亲和力的抑制剂的设计,该抑制剂能够阻止srtA与LPXTG蛋白(如InIJ)的附着。利用MODELLER(9.12版)构建了单核细胞增生李斯特菌分选酶A的同源模型。我们使用分子对接和虚拟筛选工具PyRX从锌数据库中筛选了100,000种类药物配体与srtA进行对接。使用FAFDrugs(3)网络服务器进行药代动力学分析,并基于Lipinski五规则进行ADME和毒性分析,随后对每10个连续命中结果使用PROTOX(一个服务器)进行口服毒性检查。PROTOX服务器的结果表明,配体#1(LD50为2000mg/kg)和配体#7(LD50为2000mg/kg)具有4级毒性,配体#3(LD50为14430mg/kg)具有6级毒性。随后对这些结构进行修饰,并通过FAFDrugs(3)分析以获得高生物利用度值,根据Lipinski五规则选择了配体#7。因此,建议将国际纯粹与应用化学联合会(IUPAC)名称为((R)-4-{(S)-1-[(S)-2-氨基-4-甲基戊酰基]-2-吡咯烷基}-1-[(S)-1-(乙氨基)羰基丙基氨基]-2-丙基-1,4-丁二酮)的配体#7作为srtA抑制的潜在候选物以供进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/405a/4748019/41c80726ca8e/97320630011501F1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验